We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RARE market cap is 3.22B. The company's latest EPS is USD -7.3679 and P/E is -5.30.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 100.5M | 108.31M | 98.05M | 127.39M | 108.83M |
| Operating Income | -154.11M | -147.96M | -145.1M | -122.05M | -165.35M |
| Net Income | -163.97M | -159.83M | -159.65M | -123.19M | -170.68M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 103.71M | 271.03M | 351.41M | 363.33M | 434.25M |
| Operating Income | -424.17M | -330.12M | -381.74M | -648.92M | -569.21M |
| Net Income | -402.73M | -186.57M | -454.03M | -707.42M | -606.64M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.38B | 1.31B | 1.24B | 1.49B | 1.31B |
| Total Liabilities | 1.16B | 1.18B | 1.21B | 1.22B | 1.17B |
| Total Equity | 220.48M | 129.03M | 31.71M | 275.41M | 140.26M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.14B | 1.76B | 1.52B | 1.55B | 1.49B |
| Total Liabilities | 481.73M | 605.18M | 599.84M | 1.19B | 1.22B |
| Total Equity | 653.76M | 1.15B | 922.56M | 352.49M | 275.41M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -156.87M | -273.03M | -390.9M | -474.81M | -190.73M |
| Investing | 111.3M | 210.72M | 275.02M | 168M | 94.44M |
| Financing | -722k | 32.3M | 57.53M | 388.14M | -58k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -345.38M | -132.22M | -338.71M | -380.47M | -474.81M |
| Investing | -13.04M | -179.12M | -195.37M | -291.65M | 168M |
| Financing | 679.31M | 600.27M | 118.55M | 501.21M | 388.14M |
| Market Cap | 3.22B |
| Price to Earnings Ratio | -5.30 |
| Price to Sales Ratio | 7.4 |
| Price to Cash Ratio | 15.05 |
| Price to Book Ratio | 11.67 |
| Dividend Yield | - |
| Shares Outstanding | 82.34M |
| Average Volume (1 week) | 817.65k |
| Average Volume (1 Month) | 753.03k |
| 52 Week Change | -25.62% |
| 52 Week High | 54.56 |
| 52 Week Low | 31.52 |
| Spread (Intraday) | 1.55 (3.92%) |
| Company Name | Ultragenyx Pharmaceutical Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.ultragenyx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
